Form 4: GoodRx Director Receives Equity Grant

Director Agnes Rey-Giraud was granted 73,434 restricted stock units in GoodRx Holdings, Inc.

Summary

• Director Agnes Rey-Giraud acquired 73,434 restricted stock units (RSUs) of Class A Common Stock.
• The transaction occurred on June 16, 2026.
• The RSUs represent a contingent right to receive one share of Class A common stock per unit.
• The units vest in full on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the vesting and settlement of these RSUs.

Risks

• Vesting is subject to the director's continued service through the applicable vesting date.

Future Outlook

The RSUs are scheduled to vest in full on the earlier of June 16, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure board members maintain a vested interest in the company's long-term performance.

Comparison to Industry Standards

• The use of RSUs for director compensation is consistent with standard practices for publicly traded technology and healthcare companies.
• The one-year vesting schedule is aligned with typical annual equity grant cycles for board members in the U.S. market.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual settlement of these RSUs.

Next Steps

• Vesting of the 73,434 RSUs on the earlier of June 16, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

GoodRx, GDRX, Form 4, Insider Transaction, Equity Grant, Director Compensation